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The concept that dose differentiates a medicine from a poison is the nucleus from which 
clinical pharmacology has emerged as a science and practice.1 This conceptual singularity has 
provided an organizing principle anchored in quantitative theory that defines the scope of this 
translational discipline.2 It has produced the cornerstones of the field, including 
pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug 
does to the body).2 Deriving from these core concepts, clinical pharmacology emerged as a 
discipline largely focused on developing tools and models to define fundamental relationships 
to predict therapy versus toxicology.1, 2 From these quantitative underpinnings, the revolution 
in the new biology, associated with the availability of enabling discovery platforms, in 
conjunction with the advent of increasingly more sophisticated statistical modeling approaches 
that deconvolute complex networks of information, offer the next evolutionary step for the 
discipline.3, 4 Indeed, innovations in biology, statistics and engineering have provide an 
opportunity to define the effects of drugs beyond a single molecular target, to their impact on 
entire systems of integrated signaling networks and biological processes.5, 6 In turn, systems 
pharmacology provides higher order dimensionality to drug actions that more precisely informs 
statistical models predicting concentration-response relationships, defining the framework for 
the nascent field of pharmacometrics central to enhancing drug development, regulation and 
utilization.3, 7-9 
The emergence of systems pharmacology and pharmacometrics as principle quantitative 
sciences within clinical pharmacology has been associated with the development of highly 
specialized techniques and approaches in molecular biology, engineering and modeling central 
to the practice of these subspecialties.3, 6, 7, 10 Indeed, systems biology provides an emerging 
platform that integrates complex interactions defining health and disease.11 Co-application of 
network medicine and pharmacology science for rational drug discovery and development has 
offered an unprecedented toolkit propelling most modern efficacy and safety algorithms.5 
Moreover, next generation vocabularies integrate pharmacology, clinical medicine, computer 
sciences, mathematics, quantitative biology, and systems engineering to communicate 
 4 
concepts and experimental results that define the vanguard of these fields.1, 5 In that context, 
the successful evolution of systems pharmacology and pharmacometrics is predicated on the 
nurturing of these disciplines. In turn, nurturing requires a forum where these communities can 
exchange and develop techniques, standards of practice, applications, and innovations, 
employing the lexicon and applying the concepts that define these subspecialties. 
In recognition of the burgeoning importance of pharmacometrics and systems 
pharmacology to the discipline of clinical pharmacology, the American Society for Clinical 
Pharmacology, in collaboration with Nature Publishing Group and Clinical Pharmacology and 
Therapeutics, has established CPT: Pharmacometrics and Systems Pharmacology. The 
objective of this open access journal is to create a dedicated forum for the exchange of 
information essential to the practice of these emerging disciplines. The creation of this journal 
recognizes the importance of a dedicated venue for the advancement of specialized models, 
technologies, and concepts forming the frameworks central to these communities of practice. It 
anticipates a need for public debate and discourse in these fields to catalyze evolution and the 
development of best practices. Importantly, this journal creates an opportunity for community 
dialogue employing the specialized lexicon and concepts that at once define these fields and set 
them apart from other communities of practice within clinical pharmacology 
Clinical Pharmacology and Therapeutics welcomes CPT: Pharmacometrics and Systems 
Pharmacology as the latest addition to the ASCPT publication family. It is anticipated that these 
journals will work collaboratively to advance the subspecialties of systems pharmacology and 
pharmacometrics, and the discipline of clinical pharmacology as a whole. We expect that 
manuscripts using systems pharmacology or pharmacometrics as tools to define key issues with 
broad applicability in clinical pharmacology, therapeutics and healthcare will be best suited for 
publication in Clinical Pharmacology and Therapeutics. Conversely, papers focusing on issues 
that are the specific province of systems pharmacology or pharmacometrics may be best suited 
for CPT: Pharmacometrics and Systems Pharmacology. The editorial leadership of the journals, 
and their editorial boards, will work cooperatively to ensure that the highest quality science is 
 5 
targeted to the most appropriate audience. Additionally, Clinical Pharmacology and 
Therapeutics and CPT: Pharmacometrics and Systems Pharmacology will work together to 
enhance the dissemination of advances in clinical pharmacology, systems pharmacology and 
pharmacometrics through programming at annual meetings and symposia. Clinical 
Pharmacology and Therapeutics looks forward to a productive collaboration with CPT: 
Pharmacometrics and Systems Pharmacology in this next step in the evolution of the discipline 
of human therapeutics. 
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